

Publisher: Karger
E-ISSN: 1421-9662|130|2|108-110
ISSN: 0001-5792
Source: Acta Haematologica, Vol.130, Iss.2, 2013-03, pp. : 108-110
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content


Treating Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors
Acta Haematologica, Vol. 130, Iss. 3, 2013-06 ,pp. :




HER-Targeted Tyrosine-Kinase Inhibitors
Oncology, Vol. 63, Iss. 1, 2002-11 ,pp. :




Playing Russian Roulette With Tyrosine Kinase Inhibitors
CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 3, 2013-03 ,pp. :